Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2023 | 1640 | 2.100 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 382 | 0.730 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2022 | 633 | 0.590 |
Why?
|
| DNA Repair | 2 | 2024 | 2045 | 0.590 |
Why?
|
| DNA Damage | 3 | 2024 | 2446 | 0.540 |
Why?
|
| Pyrazoles | 4 | 2021 | 2009 | 0.520 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 1896 | 0.470 |
Why?
|
| Pyrimidines | 5 | 2021 | 3028 | 0.470 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 1051 | 0.430 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1008 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 2917 | 0.310 |
Why?
|
| Adenine | 4 | 2021 | 987 | 0.260 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6814 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5671 | 0.220 |
Why?
|
| Piperidines | 4 | 2021 | 1656 | 0.220 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2020 | 647 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 5305 | 0.200 |
Why?
|
| Genomic Instability | 1 | 2024 | 709 | 0.170 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 865 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 629 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2020 | 651 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 4806 | 0.130 |
Why?
|
| Cytogenetic Analysis | 1 | 2016 | 270 | 0.130 |
Why?
|
| Genetic Markers | 2 | 2020 | 2601 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 727 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 1527 | 0.120 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 1827 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 1405 | 0.120 |
Why?
|
| Neoplasms | 1 | 2020 | 22170 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 1768 | 0.090 |
Why?
|
| Humans | 17 | 2024 | 761504 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2020 | 1978 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 6132 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 3802 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2020 | 10445 | 0.080 |
Why?
|
| Mutation | 2 | 2024 | 30052 | 0.070 |
Why?
|
| Genes, Immunoglobulin | 1 | 2008 | 285 | 0.070 |
Why?
|
| Lymphocytosis | 1 | 2008 | 121 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3877 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5671 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.060 |
Why?
|
| Prognosis | 4 | 2020 | 29625 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2019 | 6567 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12059 | 0.050 |
Why?
|
| Animals | 5 | 2024 | 168459 | 0.050 |
Why?
|
| Nucleotides | 1 | 2024 | 454 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 980 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8547 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2005 | 636 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2005 | 686 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 15936 | 0.040 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 2449 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 1858 | 0.040 |
Why?
|
| Imidazoles | 1 | 2005 | 1180 | 0.040 |
Why?
|
| Leukemia | 1 | 2024 | 1522 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2019 | 64680 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58976 | 0.030 |
Why?
|
| Karyotyping | 1 | 2017 | 1171 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 756 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 4758 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2024 | 2331 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 16981 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 1078 | 0.030 |
Why?
|
| Middle Aged | 4 | 2024 | 220895 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 18252 | 0.020 |
Why?
|
| Aged | 3 | 2020 | 169289 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2510 | 0.020 |
Why?
|
| Male | 5 | 2024 | 360804 | 0.020 |
Why?
|
| Female | 5 | 2024 | 392644 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 221177 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9486 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14414 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81525 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3602 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 3429 | 0.020 |
Why?
|
| Peptides | 1 | 2019 | 4358 | 0.020 |
Why?
|
| Disease Progression | 2 | 2017 | 13506 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 778 | 0.020 |
Why?
|
| Genes, abl | 1 | 2005 | 69 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8529 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 718 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2008 | 1525 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4920 | 0.010 |
Why?
|
| Benzamides | 1 | 2005 | 1370 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4111 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13639 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6484 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2005 | 2932 | 0.010 |
Why?
|
| Piperazines | 1 | 2005 | 2523 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23445 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18395 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 16591 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 41487 | 0.000 |
Why?
|
Concepts
(93)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_